analysts and calls -- ML Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- ML

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	3/7/2006 8:45:54 AM
	of 238

CBST Cubist Pharmaceuticals Inc (CBST, $23.44, C-1-9) Reiterate Buy. Raising PT from $30 to $33. FDA Panel Positive on Cubicin. The FDA panel voted 9-0 in favor of expanding Cubicin's label to include Staph aureus bacteremia & 5-4 in favor of expanding the label to include infective endocarditis. Comments made by FDA participants, lead us to believe that FDA may be supportive of the sNDA for Cubicin, potentially with a broader label. We think it is possible that the label may indicate Cubicin for the treatment of complicated and uncomplicated bacteremia, without noting suspected or definite endocarditis. This would be a broader label than CBST requested.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next